The capability of CD200 was further recorded in other malignancies, such as melanoma, renal cell carcinoma and ovarian tumors, using anti-CD200 antibodies, which were shown to initiate vigorous immune responses against breast cancer and other solid tumor types [54]. The gene discussed is CD200; the disease is breast carcinoma.